Opinion|Videos|November 12, 2024
Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL
Author(s)Nitin Jain, MD, Joanna M. Rhodes, MD, MSCE
Panelists discuss how they approach treatment selection for multi-refractory chronic lymphocytic leukemia (CLL) patients, considering factors such as prior therapy responses, patient fitness, and disease characteristics to guide choices among available options, including CAR T-cell therapy, while also addressing the limitations and challenges associated with each treatment modality in their decision-making process.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Which treatment options do you offer to your multi-refractory CLL patients and how do you select among available therapies?
- What key factors guide your decision to use CAR T-cell therapy in the R/R setting and what criteria do you use to select patients for this treatment?
- What are some limitations or challenges associated with these therapies and how do you weigh these into your
Advertisement
Related to this article
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
5